Neogenomics (NEO) Announces CEO Stepping Down Immediately, Morgan Stanley Offers Insights
Tweet Send to a Friend
Morgan Stanley analyst Tejas Savant reiterated an Equalweight rating and $29.00 price target on Neogenomics (NASDAQ: NEO) after catching up ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
